These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38441576)

  • 1. FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma.
    Maguire WF; Lee D; Weinstock C; Gao X; Bulik CC; Agrawal S; Chang E; Hamed SS; Bloomquist EW; Tang S; Pazdur R; Kluetz PG; Amiri-Kordestani L; Suzman DL
    Clin Cancer Res; 2024 May; 30(10):2011-2016. PubMed ID: 38441576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Powles T; Valderrama BP; Gupta S; Bedke J; Kikuchi E; Hoffman-Censits J; Iyer G; Vulsteke C; Park SH; Shin SJ; Castellano D; Fornarini G; Li JR; Gümüş M; Mar N; Loriot Y; Fléchon A; Duran I; Drakaki A; Narayanan S; Yu X; Gorla S; Homet Moreno B; van der Heijden MS;
    N Engl J Med; 2024 Mar; 390(10):875-888. PubMed ID: 38446675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
    Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA
    Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma.
    Chang E; Weinstock C; Zhang L; Charlab R; Dorff SE; Gong Y; Hsu V; Li F; Ricks TK; Song P; Tang S; Waldron PE; Yu J; Zahalka E; Goldberg KB; Pazdur R; Theoret MR; Ibrahim A; Beaver JA
    Clin Cancer Res; 2021 Feb; 27(4):922-927. PubMed ID: 32962979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
    Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
    Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
    Ning YM; Suzman D; Maher VE; Zhang L; Tang S; Ricks T; Palmby T; Fu W; Liu Q; Goldberg KB; Kim G; Pazdur R
    Oncologist; 2017 Jun; 22(6):743-749. PubMed ID: 28424325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study.
    Necchi A; Van der Heijden MS; Trukhin D; Peer A; Gurney H; Alekseev BY; Parnis FX; Leibowitz R; De Santis M; Grivas P; Clark J; Munteanu M; Kataria R; Jia C; Balar AV; de Wit R
    BMC Cancer; 2024 Jul; 23(Suppl 1):1252. PubMed ID: 39054491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer.
    Zhu X; Koshkin VS
    Med; 2024 Feb; 5(2):106-108. PubMed ID: 38128535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?
    Bellmunt J; Nadal R
    Med; 2024 Jun; 5(6):490-492. PubMed ID: 38878766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new era for bladder cancer: Enfortumab vedotin and pembrolizumab milestone approval.
    Zameer U; Shaikh W
    Tumori; 2024 Aug; 110(4):295-296. PubMed ID: 38142292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status.
    Grivas P; Plimack ER; Balar AV; Castellano D; O'Donnell PH; Bellmunt J; Powles T; Hahn NM; de Wit R; Bajorin DF; Ellison MC; Frenkl TL; Godwin JL; Vuky J
    Eur Urol Oncol; 2020 Jun; 3(3):351-359. PubMed ID: 32423837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study.
    Cicin I; Plimack ER; Gurney H; Leibowitz R; Alekseev BY; Parnis FX; Peer A; Necchi A; Bellmunt J; Nishiyama H; Clark J; Munteanu M; Kataria R; Jia C; Powles T; Sternberg CN
    BMC Cancer; 2024 Jul; 23(Suppl 1):1256. PubMed ID: 39054485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data.
    Uemura K; Ito H; Jikuya R; Kondo T; Tatenuma T; Kawahara T; Ito Y; Komeya M; Muraoka K; Hasumi H; Uemura H; Makiyama K
    Int J Urol; 2024 Jun; 31(6):678-684. PubMed ID: 38402449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
    Hoimes CJ; Flaig TW; Milowsky MI; Friedlander TW; Bilen MA; Gupta S; Srinivas S; Merchan JR; McKay RR; Petrylak DP; Sasse C; Moreno BH; Yu Y; Carret AS; Rosenberg JE
    Future Oncol; 2024 Mar; 20(7):351-360. PubMed ID: 37994649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
    Benjamin DJ; Rezazadeh Kalebasty A; Prasad V
    Eur Urol Oncol; 2024 Jun; 7(3):313-315. PubMed ID: 38485615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
    Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
    Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.
    Hoimes CJ; Flaig TW; Milowsky MI; Friedlander TW; Bilen MA; Gupta S; Srinivas S; Merchan JR; McKay RR; Petrylak DP; Sasse C; Moreno BH; Yu Y; Carret AS; Rosenberg JE
    J Clin Oncol; 2023 Jan; 41(1):22-31. PubMed ID: 36041086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
    Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
    Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab
    Minato A; Furubayashi N; Tomoda T; Masaoka H; Song Y; Hori Y; Kiyoshima K; Negishi T; Kuroiwa K; Seki N; Tomisaki I; Nakamura M; Harada K; Fujimoto N
    Anticancer Res; 2024 Aug; 44(8):3419-3426. PubMed ID: 39060065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer.
    Mamtani R; Tsingas K; Parikh RB; Elsouda D; Mucha L; Fuldeore R; Hubbard RA
    Urol Oncol; 2024 Jun; 42(6):177.e1-177.e4. PubMed ID: 38503592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.